

Alberto Palazzuoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5380223/publications.pdf>

Version: 2024-02-01

136
papers

4,139
citations

172207

29
h-index

133063

59
g-index

138
all docs

138
docs citations

138
times ranked

5583
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. <i>European Heart Journal</i> , 2010, 31, 703-711.	1.0	797
2	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
3	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1406-1416.	0.4	188
4	Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. <i>American Heart Journal</i> , 2006, 152, 1096.e9-1096.e15.	1.2	150
5	Effects of $\hat{\imath}^2$ -erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. <i>American Heart Journal</i> , 2007, 154, 645.e9-645.e15.	1.2	126
6	Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. <i>Vascular Health and Risk Management</i> , 2010, 6, 411.	1.0	121
7	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1416-1420.	0.4	118
8	Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. <i>American Journal of Medicine</i> , 2021, 134, 16-22.	0.6	105
9	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3264.	1.8	93
10	Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. <i>Journal of Clinical Medicine</i> , 2020, 9, 1683.	1.0	82
11	Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF. <i>Clinical Research in Cardiology</i> , 2018, 107, 586-596.	1.5	79
12	Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22â€^740 patients. <i>Heart</i> , 2012, 98, 914-919.	1.2	72
13	Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. <i>Critical Care</i> , 2014, 18, R134.	2.5	53
14	Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. <i>The Cochrane Library</i> , 2010, , CD007613.	1.5	50
15	Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2017, 120, 1146-1150.	0.7	48
16	Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 877-883.	1.0	46
17	Biomarkers in kidney and heart disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 62-74.	0.4	46
18	The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	0.8	46

#	ARTICLE	IF	CITATIONS
19	Comparison of Neutrophil Gelatinase-Associated Lipocalin Versus B-Type Natriuretic Peptide and Cystatin C to Predict Early Acute Kidney Injury and Outcome in Patients With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2015, 116, 104-111.	0.7	44
20	Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. <i>Critical Care</i> , 2015, 19, 296.	2.5	44
21	Epidemiology and outcome of the cardio-renal syndrome. <i>Heart Failure Reviews</i> , 2011, 16, 531-542.	1.7	42
22	Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1616-1621.	0.7	41
23	Sex-related differences in chronic heart failure. <i>International Journal of Cardiology</i> , 2018, 255, 145-151.	0.8	41
24	Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development. <i>Journal of the American Heart Association</i> , 2020, 9, e018889.	1.6	39
25	<i>H. pylori</i> infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 7815.	1.4	37
26	Cross-sectional study: CagA-positive <i>Helicobacter pylori</i> infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. <i>Journal of Clinical Pathology</i> , 2014, 67, 251-257.	1.0	36
27	Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. <i>Acute Cardiac Care</i> , 2014, 16, 93-101.	0.2	36
28	Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. <i>Heart Failure Reviews</i> , 2014, 19, 267-284.	1.7	35
29	Left Ventricular Diastolic Function Improvement by Carvedilol Therapy in Advanced Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 563-568.	0.8	31
30	Relation of Plasma Brain Natriuretic Peptide Levels in Non-ST-Elevation Coronary Disease and Preserved Systolic Function to Number of Narrowed Coronary Arteries. <i>American Journal of Cardiology</i> , 2005, 96, 1705-1710.	0.7	29
31	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , 2020, 71, 23-31.	1.0	29
32	Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. <i>Journal of the American Heart Association</i> , 2020, 9, e017364.	1.6	29
33	Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants. <i>Heart Failure Reviews</i> , 2023, 28, 597-606.	1.7	29
34	The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 641.	0.9	28
35	Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 534-548.	0.4	28
36	Hyperuricemia: a novel old disorder's relationship and potential mechanisms in heart failure. <i>Heart Failure Reviews</i> , 2020, 25, 43-51.	1.7	28

#	ARTICLE	IF	CITATIONS
37	Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Failure, 2020, 7, 4182-4188.	1.4	28
38	Brain Natriuretic Peptide and Other Risk Markers for Outcome Assessment in Patients With Non- σ -ST-Elevation Coronary Syndromes and Preserved Systolic Function. American Journal of Cardiology, 2006, 98, 1322-1328.	0.7	27
39	Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model. Respiratory Medicine, 2015, 109, 406-415.	1.3	27
40	Congestion occurrence and evaluation in acute heart failure scenario: time to reconsider different pathways of volume overload. Heart Failure Reviews, 2020, 25, 119-131.	1.7	27
41	Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clinica Chimica Acta, 2016, 457, 99-105.	0.5	26
42	Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies. Clinical Research in Cardiology, 2021, 110, 1181-1192.	1.5	26
43	Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. International Journal of Cardiology, 2016, 224, 213-219.	0.8	25
44	Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes. Heart Failure Reviews, 2011, 16, 545-551.	1.7	24
45	The role of the kidney in acute and chronic heart failure. Heart Failure Reviews, 2020, 25, 107-118.	1.7	24
46	Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine, 2020, 21, 1.	0.5	24
47	Natriuretic peptides in heart failure: where we are, where we are going. Internal and Emergency Medicine, 2011, 6, 63-68.	1.0	23
48	Left ventricular remodelling and systolic function measurement with 64 multi-slice computed tomography versus second harmonic echocardiography in patients with coronary artery disease: A double blind study. European Journal of Radiology, 2010, 73, 82-88.	1.2	22
49	Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: Relation to coronary artery narrowing and plaques number. Clinica Chimica Acta, 2008, 391, 74-79.	0.5	21
50	β -Erythropoietin Effects on Ventricular Remodeling, Left and Right Systolic Function, Pulmonary Pressure, and Hospitalizations in Patients Affected With Heart Failure and Anemia. Journal of Cardiovascular Pharmacology, 2009, 53, 462-467.	0.8	21
51	Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clinical and Experimental Medicine, 2011, 11, 43-48.	1.9	20
52	Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR- σ AHF. ESC Heart Failure, 2017, 4, 479-486.	1.4	20
53	Natriuretic peptides and NGAL in heart failure: Does a link exist?. Clinica Chimica Acta, 2012, 413, 1832-1838.	0.5	19
54	Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection. Internal and Emergency Medicine, 2015, 10, 543-554.	1.0	19

#	ARTICLE	IF	CITATIONS
55	Recent advances in pharmacological treatment of heart failure. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13624.	1.7	19
56	Effects of carvedilol therapy on restrictive diastolic filling pattern in chronic heart failure. <i>American Heart Journal</i> , 2004, 147, 73-79.	1.2	18
57	Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. <i>Heart Failure Reviews</i> , 2011, 16, 603-607.	1.7	18
58	Patients with Cardiorenal Syndrome Revealed Increased Neurohormonal Activity, Tubular and Myocardial Damage Compared to Heart Failure Patients with Preserved Renal Function. <i>CardioRenal Medicine</i> , 2014, 4, 257-268.	0.7	18
59	The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1037-1044.	0.7	18
60	The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction. <i>International Journal of Clinical Practice</i> , 2018, 72, e13050.	0.8	18
61	Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. <i>American Journal of Cardiology</i> , 2020, 137, 111-117.	0.7	18
62	Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially. <i>Heart Failure Reviews</i> , 2011, 16, 503-508.	1.7	17
63	Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 408-417.	0.6	17
64	The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 818-827.	0.6	16
65	Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. <i>Internal and Emergency Medicine</i> , 2015, 10, 41-49.	1.0	15
66	Early readmission for heart failure: An avoidable or ineluctable debacle?. <i>International Journal of Cardiology</i> , 2019, 277, 186-195.	0.8	15
67	Prognostic Significance of an Early Echocardiographic Evaluation of Right Ventricular Dimension and Function in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2020, 26, 813-820.	0.7	15
68	Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. <i>International Journal of Infectious Diseases</i> , 2020, 95, 373-375.	1.5	15
69	Heart Failure: Pathophysiology and Clinical Picture. <i>Contributions To Nephrology</i> , 2010, 164, 1-10.	1.1	14
70	Ultrasound indices of congestion in patients with acute heart failure according to body mass index. <i>Clinical Research in Cardiology</i> , 2020, 109, 1423-1433.	1.5	14
71	Transmitral and pulmonary venous flow study in elite male runners and young adults. <i>International Journal of Cardiology</i> , 2002, 84, 47-51.	0.8	13
72	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. <i>International Journal of Cardiology</i> , 2022, 350, 62-68.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Brain natriuretic peptide levels during cardiac reperfusion: comparison between percutaneous coronary angioplasty and aorto-coronary bypass. <i>Clinica Chimica Acta</i> , 2004, 342, 87-92.	0.5	12
74	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 89-97.	1.6	12
75	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. <i>ESC Heart Failure</i> , 2022, 9, 1107-1117.	1.4	12
76	The paradox of transient worsening renal function in patients with acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 851-858.	0.6	11
77	Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. <i>Canadian Journal of Physiology and Pharmacology</i> , 2022, 100, 93-106.	0.7	11
78	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. <i>Heart Failure Reviews</i> , 2023, 28, 585-596.	1.7	11
79	The Role of Natriuretic Peptides for the Diagnosis of Left Ventricular Dysfunction. <i>Scientific World Journal</i> , The, 2013, 2013, 1-10.	0.8	10
80	Clinical impact of oral antidiabetic medications in heart failure patients. <i>Heart Failure Reviews</i> , 2018, 23, 325-335.	1.7	10
81	Right heart dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 613-623.	0.6	10
82	Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 81-90.	0.6	10
83	The prognostic role of different renal function phenotypes in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2019, 276, 198-203.	0.8	10
84	Clinical, Laboratory and Lung Ultrasound Assessment of Congestion in Patients with Acute Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 1642.	1.0	10
85	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	1.0	10
86	B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function. <i>Regulatory Peptides</i> , 2011, 167, 129-133.	1.9	9
87	B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 366-373.	0.8	9
88	Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure. <i>Internal and Emergency Medicine</i> , 2017, 12, 593-603.	1.0	9
89	Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 676658.	1.1	9
90	Effects of Metolazone Administration on Congestion, Diuretic Response and Renal Function in Patients with Advanced Heart Failure. <i>Journal of Clinical Medicine</i> , 2021, 10, 4207.	1.0	9

#	ARTICLE	IF	CITATIONS
91	Clinical Impact of Renal Dysfunction in Heart Failure. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 186-199.	0.5	9
92	Pulmonary Congestion Assessment in Heart Failure: Traditional and New Tools. <i>Diagnostics</i> , 2021, 11, 1306.	1.3	8
93	Rise and fall of B-type natriuretic peptide levels in patients with coronary artery disease and normal left ventricular function after cardiac revascularization. <i>Coronary Artery Disease</i> , 2006, 17, 419-423.	0.3	7
94	Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization. <i>European Journal of Internal Medicine</i> , 2016, 30, 43-48.	1.0	7
95	Hyponatremia in Acute Heart Failure in Relation to Hematocrit Levels: Clinical Relevance and Prognostic Implication. <i>CardioRenal Medicine</i> , 2018, 8, 259-270.	0.7	7
96	Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance. <i>Heart Failure Reviews</i> , 2020, 25, 75-84.	1.7	7
97	Long-term outcome of myocardial scarring and deformation with cardiovascular magnetic resonance in out of hospital cardiac arrest survivors. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1149-1156.	0.5	7
98	Osteoprotegerin and B-type natriuretic peptide in acute coronary syndromes with preserved systolic function: Relation to coronary artery disease extension. <i>International Journal of Cardiology</i> , 2009, 137, 295-298.	0.8	6
99	Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door. <i>Heart Failure Reviews</i> , 2022, 27, 767-778.	1.7	6
100	The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 2243.	1.0	6
101	Loop Diuretic Administration in Patients with Acute Heart Failure and Reduced Systolic Function: Effects of Different Intravenous Diuretic Doses and Diuretic Response Measurements. <i>Journal of Clinical Medicine</i> , 2019, 8, 1854.	1.0	5
102	Pulmonary arterial hypertension and heart failure with preserved ejection fraction: are they so discordant?. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 534-545.	0.7	5
103	Cardiovascular Magnetic Resonance of Myocardial Fibrosis, Edema, and Infiltrates in Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 77-84.	1.0	5
104	Resistant hypertension: an overview. <i>Minerva Cardiology and Angiology</i> , 2018, 66, 337-348.	0.4	5
105	Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S182-9.	0.4	5
106	Early detection of pulmonary arterial hypertension: do not forget the right ventricle. <i>Nature Reviews Cardiology</i> , 2015, 12, 134-134.	6.1	4
107	Combined BNP and Echocardiographic assessment in interstitial lung disease for pulmonary hypertension detection. <i>International Journal of Cardiology</i> , 2015, 178, 34-36.	0.8	4
108	Arterial hypertension and atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 51-61.	0.6	4

#	ARTICLE	IF	CITATIONS
109	The use of diuretics in heart failure with congestion: we can't judge a book by its cover. ESC Heart Failure, 2019, 6, 1222-1225.	1.4	4
110	Screening, detection, and management of heart failure in the SARS-CoV2 (COVID-19) pandemic. Heart Failure Reviews, 2021, 26, 973-979.	1.7	4
111	Cardiac congestion assessed by natriuretic peptides oversimplifies the definition and treatment of heart failure. ESC Heart Failure, 2021, 8, 3453-3457.	1.4	4
112	Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF. International Journal of Molecular Sciences, 2022, 23, 4554.	1.8	4
113	Natriuretic peptides in acute chest pain and acute coronary syndrome. Coronary Artery Disease, 2013, 24, 33-39.	0.3	3
114	Hyperuricemia in US Population with Heart Failure: Causal or Incidental Bystander?. CardioRenal Medicine, 2019, 9, 341-343.	0.7	3
115	Noncardiovascular comorbidities in patients with heart failure and their impact on prognosis. Kardiologia Polska, 2021, 79, 493-502.	0.3	3
116	Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application. Current Drug Targets, 2015, 16, 1246-1253.	1.0	3
117	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. Heart Failure Reviews, 2023, 28, 683-695.	1.7	3
118	Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19. American Journal of Cardiology, 2022, , .	0.7	3
119	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study. , 2020, 2, e0220.		2
120	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. Heart Failure Reviews, 2022, 27, 135-145.	1.7	2
121	The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease. Reviews in Cardiovascular Medicine, 2021, 22, 677.	0.5	2
122	Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence. Life, 2021, 11, 395.	1.1	2
123	Nomenclature for Kidney Function from KDIGO: Shortcomings of Terminology Oversimplification. CardioRenal Medicine, 2021, 11, 1-4.	0.7	2
124	Impact of renin-angiotensin-aldosterone system inhibitor continuation on outcomes for patients with severe coronavirus disease 2019 manifestations. Journal of Hypertension, 2021, 39, 1725-1726.	0.3	2
125	Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertension. Blood Pressure, 2004, 13, 14-19.	0.7	1
126	Natriuretic Peptides in Coronary Disease With Non-ST Elevation: New Tools Ready for Clinical Application?. Recent Patents on Cardiovascular Drug Discovery, 2007, 2, 1-4.	1.5	1

#	ARTICLE	IF	CITATIONS
127	Natriuretic peptide in heart failure: where we are, where we are going. Answer to the letter. Internal and Emergency Medicine, 2011, 6, 383-383.	1.0	1
128	Unusual cardiac mass presenting as humeral artery embolisation. Journal of Clinical Pathology, 2020, 73, 57-57.	1.0	1
129	In-hospital Routes of Acute Heart Failure Admissions During COVID-19. Frontiers in Cardiovascular Medicine, 2020, 7, 581458.	1.1	1
130	Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. European Journal of Internal Medicine, 2020, 74, 125-126.	1.0	1
131	An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications. Heart Failure Reviews, 2022, , 1.	1.7	1
132	The potential role of natriuretic peptides in acute coronary syndrome stratification. Future Cardiology, 2013, 9, 297-300.	0.5	0
133	The need for evaluating right ventricular adaptation and ventriculo-arterial coupling. European Journal of Heart Failure, 2018, 20, 943-944.	2.9	0
134	Congestion occurrence and evaluation in acute heart failure scenario: author's reply to the letter. Heart Failure Reviews, 2021, 26, 733-733.	1.7	0
135	Hyperuricemia and Cardiovascular Disease. Reviews in Cardiovascular Medicine, 2017, 18, 134-145.	0.5	0
136	Different Renal Function Patterns in Patients With Acute Heart Failure: Relationship With Outcome and Congestion. Frontiers in Cardiovascular Medicine, 2022, 9, 779828.	1.1	0